Gilead Sciences News

Gilead Sciences is a multi-billion dollar biopharmaceutical company that develops medicines for a range of diseases. It is research based, so to stay up-to-date with that research, and to keep track of the performance of the company along with other issues, sign up for the Wiser Gilead Sciences news email. The drugs that Gilead Services produces treat conditions like HIV/AIDS, liver disease, cancer, cardiovascular and respiratory conditions. The company was founded in 1987 and is based in California. The president and chief executive officer is John Martin. It has about 7,000 employees and is ranked as one of the top drug companies in the US with sales in 2013 of over $11 billion. Its hepatitis-C drug, Sovaldi, is predicted to sell well, plus it is expected to continue its expansion through acquisitions. This is in addition to new drugs that the company is developing. The Gilead Sciences news email from Wiser is the best way to get the latest news and information on the company. It is free, so register today.

Recent Gilead Sciences News Coverage
 
Your Weekly Recommendations Monday, December 11, 2017
 
Recommended for you
Biotech In 2018: Will Repatriated Cash Fuel A Feeding Frenzy?
Seeking Alpha • John Engle
Gilead's new drug keeps 56 percent of lymphoma trial patients alive
Reuters • Deena Beasley
Gilead's new drug keeps 56 pct of lymphoma trial patients alive
Reuters • Deena Beasley
Gilead Sciences: Going Down When It Should Go Up
Seeking Alpha • William Meyers
Mylan wants to capture chronic Hep B market
The Economic Times of India • Prabha Raghavan
Market Snapshot: Stocks poised for higher open after stronger-than-expected jobs report
MarketWatch • Sara Sjolin
Gilead Bets on Cell Therapy Again with $567M Cell Design Labs Deal
Xconomy • Frank Vinluan
BRIEF-Gilead Sciences and Kite To Acquire Cell Design Labs
Reuters • Reuters Staff
UPDATE 1-Gilead to buy Cell Design Labs for up to $567 mln
Reuters • Reuters Staff
REFILE-Gilead to buy Cell Design Labs for up to $567 million
Reuters • Reuters Staff
 
Recommended for You
Actelion Pharmaceuticals, Gilead Sciences
Biotech In 2018: Will Repatriated Cash Fuel A Feeding Frenzy?
Seeking AlphaJohn Engle
Summary After two slow years for M&A, biotech buyout action should pick up in 2018. Uncertainty over taxes has played a large part in tamping down M&A activity; the new tax bill removes uncertainty and will result in repatriation of a huge...
Share
Cancer, Gilead Sciences
Gilead's new drug keeps 56 percent of lymphoma trial patients alive
ReutersDeena Beasley
() - More than half of trial patients with an advanced, aggressive form of blood cancer lived for at least a year after one-time treatment with Yescarta, a novel therapy sold by Gilead Sciences Inc, according to study results presented on Sunday....
Share
Cancer, Gilead Sciences
Gilead's new drug keeps 56 pct of lymphoma trial patients alive
ReutersDeena Beasley
() - More than half of trial patients with an advanced, aggressive form of blood cancer lived for at least a year after one-time treatment with Yescarta, a novel therapy sold by Gilead Sciences Inc, according to study results presented on Sunday....
Share
Accounting, Biotechnology
Gilead Sciences: Going Down When It Should Go Up
Seeking AlphaWilliam Meyers
Summary Nothing seems able to cure the post-peak Harvoni blues. Kite acquisition could take years to have a major positive earnings impact. Tax reduction would boost profits, but probably not the stock price. Gilead Sciences (GILD) is a large capitalization pharmaceutical and...
Share
Gilead Sciences
Mylan wants to capture chronic Hep B market
The Economic Times of IndiaPrabha Raghavan
NEW DELHI: US drugmaker Mylan hopes to capture a “major” share of the Rs 140-crore market for chronic Hepatitis B with the launch of its once-daily tablet for this infection in adults. The drug will have a maximum retail price of Rs...
Share
Finance, Gilead Sciences
Market Snapshot: Stocks poised for higher open after stronger-than-expected jobs report
MarketWatchSara Sjolin
Reuters Technology stocks were poised to continue their push higher on Friday, as Nasdaq futures outperformed the other major benchmarks, giving the tech sector a chance to turn higher for the week. Traders were also looking ahead to the top-tier U.S. monthly...
Share
Cancer, Gilead Sciences
Gilead Bets on Cell Therapy Again with $567M Cell Design Labs Deal
XconomyFrank Vinluan
San Francisco — Gilead Sciences is deepening its capabilities in cell therapy with a deal valued at up to $567 million to acquire Cell Design Labs, a company that discovers and develops such treatments. The announcement late Thursday comes a little more...
Share
Gilead Sciences
BRIEF-Gilead Sciences and Kite To Acquire Cell Design Labs
ReutersReuters Staff
Dec 7 () - Gilead Sciences Inc: * GILEAD SCIENCES AND KITE TO ACQUIRE CELL DESIGN LABS * GILEAD SCIENCES INC - DEAL FOR UP TO APPROXIMATELY $567 MILLION * GILEAD SCIENCES INC - AGREEMENT INCLUDES AN INITIAL UPFRONT PAYMENT OF APPROXIMATELY...
Share
Cancer, Gilead Sciences
UPDATE 1-Gilead to buy Cell Design Labs for up to $567 mln
ReutersReuters Staff
() - Drugmaker Gilead Sciences Inc (GILD.O) said on Thursday it was acquiring privately-held Cell Design Labs Inc for up to $567 million, giving it access to new technology platforms that would help in the development of cancer drugs. The deal strengthens...
Share
Cancer, Gilead Sciences
REFILE-Gilead to buy Cell Design Labs for up to $567 million
ReutersReuters Staff
(Refiles to change packaging slug) Dec 7 () - Drugmaker Gilead Sciences Inc said on Thursday it had agreed to acquire privately-held Cell Design Labs Inc for up to $567 million to boost its CAR-T cancer drug pipeline. The deal includes shares...
Share